• 1
    McCarthy JR, Matthews DP, Stemerick DM, et al. Stereospecific method to E and Z terminal fluoroolefins and its application to the synthesis of (E)-2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleotide diphosphate reductase. J Am Chem Soc. 1991; 113: 74397440.
  • 2
    Seley KL. Tezacitabine Hoechst Marion Roussel. Curr Opin Invest Drugs. 2000; 1: 135140.
  • 3
    Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995; 36: 181188.
  • 4
    Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2′-deoxy-2′-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002; 61: 222229.
  • 5
    Takahashi T, Nakashima A, Kanazawa J, et al. Metabolism and ribonucleotide reductase inhibition of (E)-2′-deoxy-2′-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells. Cancer Chemother Pharmacol. 1998; 41: 268274.
  • 6
    Piepmeier JM, Rabidou N, Schold SC Jr., Bitonti AJ, Prakash NJ, Bush TL. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res. 1996; 56: 359361.
  • 7
    Kotchetkov R, Krivtchik AA, Cinatl J, Kornhuber B, Cinatl J Jr. Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101,731 against thyroid cancer in vitro. Folia Biol (Praha). 1999; 45: 185191.
  • 8
    Bitonti AJ, Bush TL, Lewis MT, Sunkara PS. Response of human colon and prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res. 1995; 15: 11791182.
  • 9
    Bitonti AJ, Dumont JA, Bush TL, et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res. 1994; 54: 14851490.
  • 10
    Sun LQ, Li YX, Guillou L, Coucke PA. (E)-2′-deoxy-2′-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Cancer Res. 1998; 58: 54115417.
  • 11
    Matrix Pharmaceuticals. Investigator brochure. Fremont, CA: Matrix.
  • 12
    Snyder RD. Effect of 2′-deoxy-2′-(fluoromethylene) cytidine on the ultraviolet and X-ray sensitivity of HeLa cells. Oncol Res. 1994; 6: 177182.
  • 13
    Sun LQ, Li YX, Guillou L, Mirimanoff RO, Coucke PA. Antitumor and radiosensitizing effects of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice. Cancer Res. 1997; 57: 40234028.
  • 14
    Rodriguez GI, Brooks DJ, Burtness BA. Phase I clinical trials of intravenous 2′-fluoromethylene-2′-deoxycytidine (FMdC) in patients with advanced solid tumors [abstract 757]. Proc Am Soc Clin Oncol. 1999; 18: 197a.
  • 15
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 3141.
  • 16
    Clark JW, Ryan DP, Garcia-Carbonero R, et al. A phase I study of tezacitabine (FMdC) administered concurrently with continuous infusion 5-fluorouracil (5-FU) in patients with metastatic solid tumors [abstract 356]. Proc Am Soc Clin Oncol. 2001; 20: 90a.
  • 17
    Benasso M, Merlano M, Sanguineti G, et al. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. Am J Clin Oncol. 2001; 24: 618622.
  • 18
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 19
    Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001; 92: 569577.
  • 20
    Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol. 2001; 12: 541547.
  • 21
    Nagourney RA. Gemcitabine plus cisplatin in breast cancer. Oncology (Huntingt). 2001; 15(2 Suppl 3 ): 2833.
  • 22
    Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol. 2002; 29(1 Suppl 1 ): 1116.